Your AI Agent Is Only as Smart as the Intelligence Behind It
AI will change Medtech twice. First, it will change the economics of how companies sell. Then, it will change the logic by which customers decide what to buy.
Part 1 made the case for more commercial capacity without more headcount. But capacity alone raises a new question: capacity to do what, exactly? The obvious response to a more fragmented market is to give every salesperson better tools.
Soon, giving a rep an AI assistant that prepares for meetings, summarizes accounts, and suggests next steps will be unremarkable. The technology itself will not create much advantage once every competitor can buy something similar.
The important question is what that assistant knows.
Imagine a territory with 150 accounts. The CRM can tell the rep what each account bought last quarter and perhaps what was discussed during the last call. What it often cannot tell them is which customer is most likely to buy something else next.
Suppose one hospital already uses a company’s core procedural product. That fact alone is not especially useful. Now add three signals: relevant procedure volume is growing, two physicians are performing cases where an adjacent product is commonly used, and comparable hospitals with a similar procedure mix routinely use both products.
No single signal makes the opportunity obvious. Together, they reveal whitespace.
Turning Market Signals Into Decisions
That is what good commercial intelligence should do. This is the function MarketSignal is built to perform - connecting procedure volume, physician behavior, and competitive utilization into whitespace worth pursuing. It should tell the rep that the account deserves a closer look, explain why, identify the physicians or service line leaders likely to matter, show what is different about the account and provide enough context for the rep to judge whether the opportunity is real.
This is a very different problem from summarizing CRM notes.
The advantage comes from assembling patterns that no field organization can reasonably reconstruct account by account. Procedure activity, physician behavior, existing product utilization, competitive presence, account characteristics, and adoption patterns across similar customers become commercially useful when they change a decision: which account to pursue, which product to discuss, whom to engage, and why now.
Two companies can have access to equally capable models and produce very different results. One has a clearer view of where revenue is likely to emerge. The other has a faster way to search what it already knows.
That distinction will matter more than the software.
What Better-Informed Reps Actually Get
The machine can discover patterns and prepare the opportunity. The salesperson still has to determine whether the signal makes sense, understand the clinical and organizational nuance, earn trust, and move the relationship forward.
The payoff is concrete: less time researching low-probability accounts, better cross-selling, higher productivity within existing territories, and more disciplined coverage of smaller opportunities.
Part 1 was about stretching commercial reach without stretching cost at the same rate. Part 2 adds the missing condition: greater reach only works when the organization knows where to point it.
The next shift is more consequential. Sellers will not be the only ones becoming better informed. See how one medtech team put this into practice. Read the Tactile Medical case study to see how surfacing net-new whitespace saved their reps four hours a week.